Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Personalized approaches to active immunotherapy in cancer.

Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE.

Biochim Biophys Acta. 2016 Jan;1865(1):72-82. doi: 10.1016/j.bbcan.2015.07.004. Epub 2015 Aug 1. Review.

PMID:
26241169
2.

Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?

Strioga MM, Darinskas A, Pasukoniene V, Mlynska A, Ostapenko V, Schijns V.

Vaccine. 2014 Jul 7;32(32):4015-24. doi: 10.1016/j.vaccine.2014.05.006. Epub 2014 May 14. Review.

PMID:
24837511
3.

Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.

Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L, Hung SI.

J Immunol Res. 2018 Dec 19;2018:4325874. doi: 10.1155/2018/4325874. eCollection 2018. Review.

4.

The present status and future prospects of peptide-based cancer vaccines.

Hirayama M, Nishimura Y.

Int Immunol. 2016 Jul;28(7):319-28. doi: 10.1093/intimm/dxw027. Epub 2016 May 28. Review.

PMID:
27235694
5.

Advances in Therapeutic Cancer Vaccines.

Wong KK, Li WA, Mooney DJ, Dranoff G.

Adv Immunol. 2016;130:191-249. doi: 10.1016/bs.ai.2015.12.001. Epub 2016 Jan 19. Review.

PMID:
26923002
6.

Personalized dendritic cell-based tumor immunotherapy.

Janikashvili N, Larmonier N, Katsanis E.

Immunotherapy. 2010 Jan;2(1):57-68. Review.

7.

In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.

Hammerich L, Binder A, Brody JD.

Mol Oncol. 2015 Dec;9(10):1966-81. doi: 10.1016/j.molonc.2015.10.016. Epub 2015 Nov 10. Review.

8.

In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.

Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C, Jakesz R, Gnant M.

Int J Oncol. 2003 Mar;22(3):651-6.

PMID:
12579320
9.

Current state and perspectives of dendritic cell vaccination in cancer immunotherapy.

Farkas A, Conrad C, Tonel G, Borbenyi Z, Kemeny L, Dobozy A, Nestle FO.

Skin Pharmacol Physiol. 2006;19(3):124-31. Epub 2006 Apr 6. Review.

PMID:
16612139
10.

Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.

Osada T, Nagaoka K, Takahara M, Yang XY, Liu CX, Guo H, Roy Choudhury K, Hobeika A, Hartman Z, Morse MA, Lyerly HK.

J Immunother. 2015 May;38(4):155-64. doi: 10.1097/CJI.0000000000000075.

PMID:
25839441
11.

Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Seledtsov VI, Goncharov AG, Seledtsova GV.

Hum Vaccin Immunother. 2015;11(4):851-69. doi: 10.1080/21645515.2015.1009814. Review.

12.

Cancer vaccines.

Butterfield LH.

BMJ. 2015 Apr 22;350:h988. doi: 10.1136/bmj.h988. Review.

13.

A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia.

Kronenberger K, Nössner E, Frankenberger B, Wahl U, Dreyling M, Hallek M, Mocikat R.

J Immunother. 2008 Oct;31(8):723-30. doi: 10.1097/CJI.0b013e318183af26.

PMID:
18779747
14.

Personalized vaccines for cancer immunotherapy.

Sahin U, Türeci Ö.

Science. 2018 Mar 23;359(6382):1355-1360. doi: 10.1126/science.aar7112. Review.

PMID:
29567706
15.

Personalized cancer vaccines.

Jain KK.

Expert Opin Biol Ther. 2010 Dec;10(12):1637-47. doi: 10.1517/14712598.2010.531256. Epub 2010 Oct 28. Review.

PMID:
20979567
16.

Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens.

Wagner S, Mullins CS, Linnebacher M.

World J Gastroenterol. 2018 Dec 28;24(48):5418-5432. doi: 10.3748/wjg.v24.i48.5418. Review.

17.

Next generation approaches for tumor vaccination.

Patel A, Kaufman HL, Disis ML.

Chin Clin Oncol. 2017 Apr;6(2):19. doi: 10.21037/cco.2017.02.04. Review.

18.

Tumor cell lysates as immunogenic sources for cancer vaccine design.

González FE, Gleisner A, Falcón-Beas F, Osorio F, López MN, Salazar-Onfray F.

Hum Vaccin Immunother. 2014;10(11):3261-9. doi: 10.4161/21645515.2014.982996. Review.

19.

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.

Bendjama K, Quemeneur E.

Hum Vaccin Immunother. 2017 Sep 2;13(9):1997-2003. doi: 10.1080/21645515.2017.1334746. Epub 2017 Aug 28.

20.

Cancer Neoantigens and Applications for Immunotherapy.

Desrichard A, Snyder A, Chan TA.

Clin Cancer Res. 2016 Feb 15;22(4):807-12. doi: 10.1158/1078-0432.CCR-14-3175. Epub 2015 Oct 29. Review.

Supplemental Content

Support Center